The Global Clostridium Diagnostics Industry is anticipated to grow at a 12.2% CAGR from 2022 to 2032, from US$ 2.5 billion to US$ 7.8 billion. The market saw a 13.6% CAGR between 2015 and 2021. The market is expanding as a result of increased awareness-raising activities for clostridium-related illnesses and their rising prevalence.
There has been an increased focus of players in the market to offer vaccines, which can augment the market size in the forecast period. For instance, in March 2022, Japan launched a new center, with a budget of US$ 1.6 Billion, to support vaccine and drug projects as a part of a larger scheme to tackle infectious diseases. SCARDA will be in charge of establishing a flagship R&D site for innovative collaborations and controlling funds for R&D projects.
Awareness campaigns are expected to play important role in driving the market during the forecast period. For instance, the ‘See C. diff’ campaign, launched by Peggy Lillis Foundation in December 2020, attained its objective by reaching more than 250,000 Americans. The organization launched the ‘See C. diff’ to commemorate C.diff Awareness Month in 2019, and reached about 80,000 people.
Request a Sample of this Report Now!
https://www.futuremarketinsights.com/reports/sample/rep-gb-15203
The launch of new vaccines in the market is another vital factor driving the market during the forecast period. For instance, in August 2021, Huvepharma Canada Corporation Inc. launched a new vaccine that has been shown to be effective against necrotic enteritis (NE) due to Clostridium perfringens type A in broiler chickens.
In addition, emerging companies such as, Acurx Pharmaceuticals, Cubist Pharmaceuticals, Endo Aesthetics, Avisa Pharma, and MGB Bio Pharma are expected to make a significant contribution in developing the market during the forecast period. However, lack of awareness and scarcity of resources in developing countries are expected to hamper the market growth during the forecast period. Also, the high costs involved in R&D and vaccine manufacturing are expected to be other factors hindering the market growth in the assessment period.
However, growing partnerships among players are projected to counter the hampering factors and boost the market. For instance, in March 2021, Peggy Lillis Foundation for Clostridium difficile infections announced a partnership with Ferring Pharmaceutical through a new sponsorship to assist new and existing patient advocacy initiatives.
Key Takeaways from the Market Study:
- The immunoassays technology is expected to dominate the Global Clostridium Diagnostics Industry at a CAGR of 11.6% during 2022-2032
- The clostridium diagnostics market in the U.S is anticipated to display a CAGR of 11.8% during the forecast period
- The U.K clostridium diagnostics market is predicted to hold a market value worth US$ 330 Million by 2032
- The Japanese clostridium diagnostics market is estimated at a CAGR of 11.1% during the forecast period.
“Growing launch of new vaccines by various players of the market along with the increasing popularity of awareness campaigns as a useful tool for market growth is expected to play a significant role in driving the market during the forecast period,” says an FMI analyst.
Click here to buy your full report
https://www.futuremarketinsights.com/checkout/15203
Global Clostridium Diagnostics Industry Competition Analysis
- Abbott Laboratories
- F. Hoffmann La-Roche AG
- Siemens AG
- Becton, Dickinson & Company
- Beckman Coulter Inc.
- Sysmex India Pvt. Ltd.
- Thermo Fisher Scientific Inc.
- Fujirebio US Inc.
- BioMerieux S.A
- Diazyme Laboratories Inc.
Key Segments Profiled In The Global Clostridium Diagnostics Industry
Global Clostridium Diagnostics Industry by Technology:
- Immunoassays-based Clostridium Diagnostics
- Molecular Clostridium Diagnostics
Global Clostridium Diagnostics Industry by End User:
- Clostridium Diagnostics in Hospitals
- Clostridium Diagnostics in Government Diagnostics Laboratories
- Clostridium Diagnostics in Independent Laboratories
Global Clostridium Diagnostics Industry by Product:
- Clostridium Difficile Diagnostics
- Clostridium Perfringens Diagnostics
- Clostridium Botulinum Diagnostics
- Clostridium Tetani Diagnostics
- Clostridium Sordell Diagnostics
Click Here To Buy Your Detailed Report
https://www.futuremarketinsights.com/checkout/15203
Author
Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.
Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.
Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, Stevie Award – recipient market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
